Varenne Capital Partners Takes $9.95 Million Position in CVS Health Corporation $CVS

Varenne Capital Partners purchased a new position in shares of CVS Health Corporation (NYSE:CVS) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 131,950 shares of the pharmacy operator’s stock, valued at approximately $9,948,000. CVS Health accounts for approximately 1.9% of Varenne Capital Partners’ holdings, making the stock its 14th biggest position.

Other large investors have also bought and sold shares of the company. Norges Bank bought a new stake in shares of CVS Health during the 2nd quarter valued at $1,358,698,000. Invesco Ltd. grew its stake in shares of CVS Health by 15.3% during the second quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after purchasing an additional 3,118,626 shares during the period. Vanguard Group Inc. increased its holdings in CVS Health by 1.7% in the second quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock valued at $8,305,132,000 after purchasing an additional 2,063,737 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in CVS Health by 153.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 3,105,827 shares of the pharmacy operator’s stock valued at $214,240,000 after buying an additional 1,878,217 shares during the period. Finally, Panagora Asset Management Inc. boosted its holdings in CVS Health by 2,675.7% during the second quarter. Panagora Asset Management Inc. now owns 1,116,742 shares of the pharmacy operator’s stock worth $77,033,000 after buying an additional 1,076,509 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Stock Down 1.5%

Shares of CVS stock opened at $80.41 on Wednesday. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. The firm has a fifty day moving average of $78.50 and a 200-day moving average of $77.47. The company has a market capitalization of $102.30 billion, a price-to-earnings ratio of 58.27, a P/E/G ratio of 0.85 and a beta of 0.49.

CVS Health (NYSE:CVS) last announced its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same period in the prior year, the business earned $1.19 EPS. The company’s revenue for the quarter was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities research analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health’s dividend payout ratio (DPR) is currently 192.75%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Truist Financial set a $100.00 price target on shares of CVS Health in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CVS Health in a research note on Monday, December 29th. TD Cowen lifted their price target on shares of CVS Health from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Bank of America lowered their price objective on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, January 27th. Finally, JPMorgan Chase & Co. raised their price objective on CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Nineteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.77.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.